Providers Seek More Relief While GOP Scrutinizes Uninsured Program

HHS’ latest provider relief distribution cast aside providers’ calls for the administration to reimburse costs or losses from the Delta or Omicron surges, and providers face un uphill battle as the Biden administration is only asking Congress to add funds to the uninsured reimbursement pot -- a multibillion dollar fund drawn in part from provider relief that Republicans are highly critical of. The agency in charge of releasing provider relief, the Health Resources and Services Administration, announced Thursday (Feb. 24)...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 03/03/2022
CMS Volume: 
Vol. 25, No. 9
HEA Issue: 
Health Exchange Alert Weekly Report - 03/02/2022
HEA Volume: 
Vol. 10, No. 9

Gottheimer Entertains Longer Exclusivity For Drugs Stalled By Pandemic

Rep. Josh Gottheimer (D-NJ) said Thursday (Feb. 24) that he would entertain lengthening exclusivity periods to give drug makers back some of the patent life they lost on rare-disease drugs due to stalled research and development during the pandemic. Gottheimer was pitched the idea during an event on rare disease research organized by The Hill . Editor at large Steven Clemons, who moderated the event, said drug makers told him they had lost patent time during the pandemic because they...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 02/28/2022
IDP Volume: 
Vol. 5, No. 9
Author: 

Experts Say Diverse Future Of Health Care Depends On HBCU Pipeline

Black children, students from historically black colleges and universities (HBCUs) and young professionals of color will play a critical role in advancing equity in health care, but it will take a concerted effort from schools, employers and CMS to strengthen the pipeline of future medical professionals from Black communities -- an effort that should begin as early as middle school, said CMS Administrator Chiquita Brooks-LaSure and a panel of Black women doctors during a round table discussion Thursday (Feb. 24)...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 03/03/2022
CMS Volume: 
Vol. 25, No. 9
Author: 

Students Ask HHS To Recuse NIH Adviser From March-In Decision

The Universities Allied for Essential Medicines is requesting that HHS recuse Mark Rohrbaugh, special adviser for technology transfer at the National Institutes of Health, from advising NIH on its handling of a petition for the government to march in on patents for the prostate cancer drug Xtandi. The global student group says Rohrbaugh is biased against using march-in authority to control drug prices. The request is the latest in a series of updates following NIH’s decision in December to review...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 02/28/2022
IDP Volume: 
Vol. 5, No. 9
Author: 










Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.